Targeted therapy shows unique promise in mutation-driven cancers: when BRAF inhibitors are combined with oncolytic herpes simplex virus (HSV) and checkpoint inhibitors, the complete response rate in BRAF-mutated thyroid cancer reaches 93%, accompanied by significant changes in immune cell activation markers and interferon signaling pathways [132,173]. Here, BRAF is linked to thyroid gland carcinoma.